| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholangiocarcinoma | 59 | 2024 | 493 | 12.110 |
Why?
|
| Bile Duct Neoplasms | 53 | 2024 | 493 | 10.410 |
Why?
|
| Biliary Tract Neoplasms | 19 | 2023 | 167 | 6.080 |
Why?
|
| Gallbladder Neoplasms | 20 | 2023 | 245 | 4.270 |
Why?
|
| Pancreatic Neoplasms | 66 | 2024 | 5061 | 3.680 |
Why?
|
| Bile Ducts, Intrahepatic | 32 | 2024 | 334 | 3.250 |
Why?
|
| Deoxycytidine | 34 | 2023 | 1353 | 2.330 |
Why?
|
| Carcinoma, Pancreatic Ductal | 25 | 2024 | 1724 | 2.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 59 | 2023 | 15862 | 2.060 |
Why?
|
| Adenocarcinoma | 40 | 2020 | 7789 | 1.650 |
Why?
|
| Phenylurea Compounds | 4 | 2021 | 580 | 1.410 |
Why?
|
| Esophageal Neoplasms | 18 | 2010 | 3168 | 1.300 |
Why?
|
| DNA Repair | 5 | 2020 | 1872 | 1.170 |
Why?
|
| Pyrimidines | 6 | 2021 | 3518 | 1.160 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 3 | 2023 | 182 | 1.130 |
Why?
|
| Humans | 232 | 2024 | 261506 | 1.080 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 5 | 2023 | 96 | 1.080 |
Why?
|
| Liver Neoplasms | 19 | 2022 | 4557 | 1.070 |
Why?
|
| Fluorouracil | 22 | 2021 | 1944 | 1.070 |
Why?
|
| Carcinoma, Hepatocellular | 12 | 2022 | 2027 | 1.060 |
Why?
|
| Isocitrate Dehydrogenase | 4 | 2024 | 480 | 1.040 |
Why?
|
| Receptors, Fibroblast Growth Factor | 3 | 2021 | 153 | 1.030 |
Why?
|
| Middle Aged | 127 | 2024 | 86204 | 1.010 |
Why?
|
| Aged | 120 | 2021 | 70117 | 0.990 |
Why?
|
| Mutation | 30 | 2024 | 15179 | 0.980 |
Why?
|
| Gastrointestinal Neoplasms | 7 | 2011 | 600 | 0.980 |
Why?
|
| Antineoplastic Agents | 24 | 2024 | 14289 | 0.950 |
Why?
|
| Erlotinib Hydrochloride | 7 | 2018 | 388 | 0.950 |
Why?
|
| Biomarkers, Tumor | 26 | 2024 | 10331 | 0.930 |
Why?
|
| Neoplasms, Unknown Primary | 3 | 2022 | 192 | 0.880 |
Why?
|
| Male | 136 | 2024 | 123000 | 0.870 |
Why?
|
| Liver Transplantation | 5 | 2022 | 1112 | 0.830 |
Why?
|
| Adult | 100 | 2023 | 77950 | 0.830 |
Why?
|
| Female | 139 | 2024 | 141928 | 0.810 |
Why?
|
| Aged, 80 and over | 62 | 2021 | 29902 | 0.810 |
Why?
|
| Antibodies, Monoclonal, Humanized | 10 | 2022 | 3251 | 0.810 |
Why?
|
| BRCA1 Protein | 4 | 2021 | 493 | 0.790 |
Why?
|
| Organoplatinum Compounds | 13 | 2020 | 702 | 0.780 |
Why?
|
| DNA Mutational Analysis | 7 | 2021 | 2283 | 0.770 |
Why?
|
| Capecitabine | 12 | 2022 | 388 | 0.770 |
Why?
|
| Maximum Tolerated Dose | 15 | 2024 | 1290 | 0.750 |
Why?
|
| Pyrroles | 2 | 2021 | 576 | 0.750 |
Why?
|
| BRCA2 Protein | 3 | 2017 | 358 | 0.720 |
Why?
|
| Neoplasm Metastasis | 14 | 2021 | 5112 | 0.720 |
Why?
|
| Prognosis | 46 | 2023 | 21713 | 0.720 |
Why?
|
| Morpholines | 1 | 2021 | 289 | 0.710 |
Why?
|
| Signal Transduction | 16 | 2021 | 11965 | 0.710 |
Why?
|
| Survival Rate | 31 | 2021 | 12221 | 0.700 |
Why?
|
| Antibodies, Monoclonal | 8 | 2023 | 4367 | 0.700 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2024 | 425 | 0.690 |
Why?
|
| Phthalazines | 1 | 2021 | 253 | 0.680 |
Why?
|
| Receptor, ErbB-2 | 2 | 2021 | 2518 | 0.670 |
Why?
|
| Trastuzumab | 1 | 2021 | 696 | 0.660 |
Why?
|
| Programmed Cell Death 1 Receptor | 4 | 2021 | 1048 | 0.660 |
Why?
|
| Receptors, Somatomedin | 2 | 2018 | 70 | 0.650 |
Why?
|
| High-Throughput Nucleotide Sequencing | 13 | 2022 | 2291 | 0.650 |
Why?
|
| Hypertension | 2 | 2024 | 1503 | 0.650 |
Why?
|
| Retrospective Studies | 57 | 2024 | 37905 | 0.630 |
Why?
|
| Pancreatectomy | 8 | 2022 | 652 | 0.630 |
Why?
|
| Albumins | 6 | 2023 | 258 | 0.620 |
Why?
|
| Neoplasms | 20 | 2024 | 15193 | 0.620 |
Why?
|
| B7-H1 Antigen | 2 | 2024 | 1022 | 0.610 |
Why?
|
| Gene Expression Profiling | 8 | 2020 | 5159 | 0.610 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2024 | 1546 | 0.580 |
Why?
|
| Neoadjuvant Therapy | 20 | 2023 | 4975 | 0.580 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 6 | 2023 | 1331 | 0.570 |
Why?
|
| Antimetabolites, Antineoplastic | 9 | 2020 | 1299 | 0.560 |
Why?
|
| Paclitaxel | 8 | 2023 | 1996 | 0.560 |
Why?
|
| Molecular Targeted Therapy | 11 | 2020 | 2330 | 0.560 |
Why?
|
| Pancreaticoduodenectomy | 7 | 2017 | 690 | 0.560 |
Why?
|
| Neoplasm Staging | 34 | 2021 | 13658 | 0.560 |
Why?
|
| Treatment Outcome | 48 | 2023 | 32848 | 0.540 |
Why?
|
| Stomach Neoplasms | 8 | 2014 | 2278 | 0.540 |
Why?
|
| Anthraquinones | 1 | 2015 | 27 | 0.530 |
Why?
|
| Smad4 Protein | 2 | 2014 | 196 | 0.530 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2007 | 460 | 0.520 |
Why?
|
| Transforming Growth Factor beta | 3 | 2016 | 1130 | 0.500 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2021 | 1249 | 0.490 |
Why?
|
| Neovascularization, Pathologic | 2 | 2014 | 1547 | 0.490 |
Why?
|
| Immunotherapy | 6 | 2020 | 3341 | 0.480 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2018 | 347 | 0.480 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2008 | 5437 | 0.480 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2024 | 1215 | 0.480 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2014 | 1248 | 0.480 |
Why?
|
| Cell-Free Nucleic Acids | 3 | 2022 | 224 | 0.470 |
Why?
|
| Chemoradiotherapy | 10 | 2017 | 1946 | 0.460 |
Why?
|
| Genes, BRCA2 | 1 | 2016 | 309 | 0.460 |
Why?
|
| Protein Kinase Inhibitors | 9 | 2024 | 4757 | 0.460 |
Why?
|
| Germ-Line Mutation | 5 | 2019 | 1046 | 0.460 |
Why?
|
| Genomics | 6 | 2023 | 2738 | 0.450 |
Why?
|
| Genes, BRCA1 | 1 | 2016 | 387 | 0.450 |
Why?
|
| Quinazolines | 7 | 2021 | 923 | 0.450 |
Why?
|
| Survival Analysis | 21 | 2020 | 9180 | 0.450 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2010 | 2054 | 0.450 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2014 | 229 | 0.430 |
Why?
|
| Hedgehog Proteins | 1 | 2015 | 424 | 0.430 |
Why?
|
| Sulfonamides | 2 | 2015 | 1823 | 0.430 |
Why?
|
| Neoplasm Proteins | 9 | 2020 | 3230 | 0.420 |
Why?
|
| Circulating Tumor DNA | 3 | 2022 | 235 | 0.420 |
Why?
|
| ErbB Receptors | 8 | 2018 | 2295 | 0.410 |
Why?
|
| Combined Modality Therapy | 22 | 2018 | 8865 | 0.410 |
Why?
|
| Ampulla of Vater | 3 | 2017 | 155 | 0.410 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2022 | 10035 | 0.410 |
Why?
|
| Pyrazoles | 3 | 2021 | 1471 | 0.380 |
Why?
|
| Disease-Free Survival | 17 | 2022 | 10001 | 0.380 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2022 | 272 | 0.370 |
Why?
|
| Congresses as Topic | 2 | 2010 | 298 | 0.370 |
Why?
|
| Hypertension, Portal | 2 | 2024 | 124 | 0.360 |
Why?
|
| Disease Progression | 15 | 2021 | 6682 | 0.360 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2011 | 324 | 0.360 |
Why?
|
| Cisplatin | 11 | 2023 | 2432 | 0.360 |
Why?
|
| Preoperative Care | 7 | 2021 | 1529 | 0.350 |
Why?
|
| Carcinoma | 5 | 2016 | 2578 | 0.340 |
Why?
|
| Proto-Oncogene Proteins B-raf | 8 | 2024 | 1283 | 0.330 |
Why?
|
| Precision Medicine | 6 | 2021 | 1154 | 0.330 |
Why?
|
| Camptothecin | 4 | 2008 | 517 | 0.330 |
Why?
|
| STAT3 Transcription Factor | 1 | 2015 | 1121 | 0.320 |
Why?
|
| Medical Oncology | 4 | 2020 | 1423 | 0.320 |
Why?
|
| Pyrimidinones | 2 | 2020 | 314 | 0.320 |
Why?
|
| Colorectal Neoplasms | 5 | 2024 | 3578 | 0.310 |
Why?
|
| Administration, Oral | 4 | 2021 | 1544 | 0.310 |
Why?
|
| Cell Proliferation | 6 | 2017 | 7226 | 0.310 |
Why?
|
| Pyridones | 2 | 2020 | 348 | 0.310 |
Why?
|
| CA-19-9 Antigen | 5 | 2020 | 144 | 0.300 |
Why?
|
| Gastric Emptying | 1 | 2007 | 94 | 0.300 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 3 | 2023 | 160 | 0.300 |
Why?
|
| Incidence | 7 | 2022 | 5673 | 0.290 |
Why?
|
| Gastrointestinal Motility | 1 | 2007 | 92 | 0.290 |
Why?
|
| Gastrointestinal Agents | 1 | 2007 | 108 | 0.290 |
Why?
|
| Radiation-Sensitizing Agents | 3 | 2021 | 363 | 0.290 |
Why?
|
| Enzyme Inhibitors | 3 | 2022 | 1879 | 0.290 |
Why?
|
| Chemotherapy, Adjuvant | 12 | 2020 | 3890 | 0.290 |
Why?
|
| Gastroparesis | 1 | 2007 | 72 | 0.290 |
Why?
|
| Quality of Life | 5 | 2023 | 4532 | 0.290 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2019 | 5539 | 0.280 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2024 | 1533 | 0.280 |
Why?
|
| Mucositis | 1 | 2007 | 148 | 0.280 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2007 | 108 | 0.270 |
Why?
|
| Pancreatic Cyst | 1 | 2007 | 107 | 0.270 |
Why?
|
| Common Bile Duct Neoplasms | 2 | 2017 | 145 | 0.270 |
Why?
|
| Phosphorylation | 6 | 2015 | 4804 | 0.270 |
Why?
|
| Intestinal Neoplasms | 2 | 2017 | 189 | 0.260 |
Why?
|
| Mesoderm | 1 | 2007 | 404 | 0.260 |
Why?
|
| Cholangitis | 2 | 2024 | 48 | 0.260 |
Why?
|
| Kaplan-Meier Estimate | 15 | 2021 | 6207 | 0.260 |
Why?
|
| Clinical Trials as Topic | 5 | 2021 | 3719 | 0.260 |
Why?
|
| Exosomes | 2 | 2018 | 253 | 0.260 |
Why?
|
| Epithelium | 1 | 2007 | 720 | 0.260 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2021 | 7551 | 0.250 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2005 | 534 | 0.250 |
Why?
|
| Gallstones | 2 | 2022 | 62 | 0.250 |
Why?
|
| Pyridines | 4 | 2021 | 1244 | 0.250 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 3 | 2016 | 479 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 5 | 2020 | 2403 | 0.240 |
Why?
|
| Benzimidazoles | 2 | 2018 | 428 | 0.240 |
Why?
|
| Apoptosis | 3 | 2016 | 7591 | 0.240 |
Why?
|
| Young Adult | 14 | 2023 | 21445 | 0.240 |
Why?
|
| Prospective Studies | 12 | 2024 | 12873 | 0.240 |
Why?
|
| Immunoenzyme Techniques | 4 | 2016 | 1165 | 0.240 |
Why?
|
| Follow-Up Studies | 17 | 2021 | 14889 | 0.240 |
Why?
|
| Consensus | 4 | 2021 | 978 | 0.240 |
Why?
|
| Peptides | 2 | 2007 | 1479 | 0.240 |
Why?
|
| Rare Diseases | 2 | 2018 | 351 | 0.240 |
Why?
|
| Intestine, Small | 2 | 2017 | 499 | 0.230 |
Why?
|
| Lymphatic Metastasis | 6 | 2021 | 4844 | 0.230 |
Why?
|
| Double-Blind Method | 4 | 2021 | 2588 | 0.230 |
Why?
|
| Drug Hypersensitivity | 1 | 2004 | 128 | 0.230 |
Why?
|
| Neoplasms, Experimental | 1 | 2007 | 750 | 0.230 |
Why?
|
| Epilepsy, Benign Neonatal | 1 | 2022 | 12 | 0.220 |
Why?
|
| Lung Neoplasms | 6 | 2024 | 11538 | 0.220 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2023 | 77 | 0.220 |
Why?
|
| Dyskinesias | 1 | 2022 | 18 | 0.220 |
Why?
|
| Carcinoma, Small Cell | 1 | 2005 | 408 | 0.220 |
Why?
|
| Multivariate Analysis | 6 | 2021 | 4298 | 0.220 |
Why?
|
| Muscle Neoplasms | 1 | 2003 | 109 | 0.220 |
Why?
|
| United States | 10 | 2022 | 15433 | 0.220 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2020 | 755 | 0.210 |
Why?
|
| Deglutition Disorders | 1 | 2006 | 447 | 0.210 |
Why?
|
| Thigh | 1 | 2003 | 172 | 0.210 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2003 | 170 | 0.210 |
Why?
|
| Time Factors | 11 | 2021 | 12926 | 0.210 |
Why?
|
| Gallbladder | 1 | 2021 | 69 | 0.210 |
Why?
|
| Palliative Care | 5 | 2015 | 2037 | 0.200 |
Why?
|
| Central Serous Chorioretinopathy | 1 | 2021 | 7 | 0.200 |
Why?
|
| Glycine | 2 | 2021 | 289 | 0.200 |
Why?
|
| Hyperphosphatemia | 1 | 2021 | 18 | 0.200 |
Why?
|
| Bevacizumab | 5 | 2016 | 938 | 0.200 |
Why?
|
| Leucovorin | 4 | 2020 | 332 | 0.200 |
Why?
|
| Immunohistochemistry | 11 | 2021 | 7548 | 0.200 |
Why?
|
| Esophagectomy | 5 | 2007 | 911 | 0.200 |
Why?
|
| Cholecystectomy | 3 | 2022 | 107 | 0.190 |
Why?
|
| Venous Thrombosis | 2 | 2013 | 384 | 0.190 |
Why?
|
| Alopecia | 1 | 2021 | 126 | 0.190 |
Why?
|
| Intestinal Mucosa | 1 | 2007 | 1081 | 0.190 |
Why?
|
| Quinoxalines | 1 | 2021 | 95 | 0.190 |
Why?
|
| Retinal Detachment | 1 | 2021 | 88 | 0.190 |
Why?
|
| Benzamides | 2 | 2020 | 1832 | 0.190 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2015 | 1062 | 0.190 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2020 | 26 | 0.190 |
Why?
|
| Stomatitis | 1 | 2021 | 183 | 0.190 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2024 | 992 | 0.190 |
Why?
|
| Colonic Neoplasms | 3 | 2018 | 1390 | 0.180 |
Why?
|
| Esophagus | 1 | 2004 | 553 | 0.180 |
Why?
|
| Proportional Hazards Models | 8 | 2021 | 4988 | 0.180 |
Why?
|
| Drug Administration Schedule | 5 | 2020 | 3472 | 0.180 |
Why?
|
| Aniline Compounds | 1 | 2021 | 177 | 0.180 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2011 | 2231 | 0.180 |
Why?
|
| Cyclooxygenase 2 | 3 | 2006 | 483 | 0.180 |
Why?
|
| Bacterial Infections | 2 | 2021 | 479 | 0.180 |
Why?
|
| Antiemetics | 1 | 2021 | 125 | 0.180 |
Why?
|
| Safety | 1 | 2021 | 465 | 0.180 |
Why?
|
| Genome, Human | 2 | 2020 | 1869 | 0.170 |
Why?
|
| Bayes Theorem | 1 | 2024 | 1021 | 0.170 |
Why?
|
| Oximes | 1 | 2020 | 175 | 0.170 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2014 | 665 | 0.170 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2020 | 1763 | 0.170 |
Why?
|
| Ergocalciferols | 1 | 2018 | 12 | 0.170 |
Why?
|
| Germ Cells | 1 | 2021 | 335 | 0.170 |
Why?
|
| Biliary Tract Surgical Procedures | 2 | 2017 | 42 | 0.170 |
Why?
|
| Prodrugs | 1 | 2020 | 217 | 0.160 |
Why?
|
| Klatskin Tumor | 1 | 2018 | 29 | 0.160 |
Why?
|
| Microsatellite Instability | 1 | 2020 | 400 | 0.160 |
Why?
|
| Radiology, Interventional | 1 | 2020 | 138 | 0.160 |
Why?
|
| Postoperative Care | 2 | 2020 | 739 | 0.160 |
Why?
|
| Stents | 4 | 2017 | 1096 | 0.160 |
Why?
|
| Gene Frequency | 2 | 2019 | 1163 | 0.160 |
Why?
|
| Sirolimus | 2 | 2015 | 814 | 0.160 |
Why?
|
| Cell Line, Tumor | 9 | 2024 | 14551 | 0.160 |
Why?
|
| Genetic Heterogeneity | 2 | 2017 | 318 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2020 | 8873 | 0.160 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2016 | 311 | 0.160 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2018 | 53 | 0.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2024 | 5319 | 0.160 |
Why?
|
| Clinical Protocols | 1 | 2020 | 467 | 0.160 |
Why?
|
| Predictive Value of Tests | 6 | 2021 | 4892 | 0.150 |
Why?
|
| Interleukin-10 | 1 | 2020 | 478 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2020 | 4938 | 0.150 |
Why?
|
| Dry Eye Syndromes | 1 | 2021 | 286 | 0.150 |
Why?
|
| Osteonectin | 1 | 2017 | 53 | 0.150 |
Why?
|
| Inpatients | 1 | 2023 | 678 | 0.150 |
Why?
|
| Mice, Nude | 2 | 2015 | 4307 | 0.150 |
Why?
|
| Heterozygote | 2 | 2017 | 1020 | 0.150 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2017 | 69 | 0.150 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2017 | 44 | 0.150 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2017 | 85 | 0.150 |
Why?
|
| Carcinoma, Ductal | 1 | 2018 | 145 | 0.150 |
Why?
|
| Ascites | 1 | 2017 | 198 | 0.150 |
Why?
|
| Portal Vein | 2 | 2017 | 355 | 0.150 |
Why?
|
| Pyrazines | 1 | 2020 | 495 | 0.150 |
Why?
|
| Proton Therapy | 2 | 2019 | 1577 | 0.150 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 615 | 0.140 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2017 | 105 | 0.140 |
Why?
|
| Myocardial Infarction | 1 | 2006 | 1374 | 0.140 |
Why?
|
| Antigens, CD | 1 | 2021 | 1385 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2008 | 259 | 0.140 |
Why?
|
| Seizures | 1 | 2022 | 989 | 0.140 |
Why?
|
| Liver X Receptors | 1 | 2016 | 31 | 0.140 |
Why?
|
| Antigens, Neoplasm | 2 | 2020 | 1506 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2015 | 3821 | 0.140 |
Why?
|
| Gene Fusion | 1 | 2017 | 209 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 598 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2020 | 5178 | 0.140 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2017 | 160 | 0.140 |
Why?
|
| Drainage | 3 | 2018 | 416 | 0.140 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2021 | 1823 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2008 | 280 | 0.140 |
Why?
|
| Pancreatic Fistula | 1 | 2016 | 99 | 0.140 |
Why?
|
| Case-Control Studies | 8 | 2023 | 6100 | 0.140 |
Why?
|
| Gelatin | 1 | 2005 | 49 | 0.140 |
Why?
|
| Acrylic Resins | 1 | 2005 | 43 | 0.140 |
Why?
|
| Beckwith-Wiedemann Syndrome | 1 | 2016 | 38 | 0.140 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2016 | 222 | 0.130 |
Why?
|
| Calcitriol | 2 | 2006 | 127 | 0.130 |
Why?
|
| Carboplatin | 1 | 2018 | 823 | 0.130 |
Why?
|
| Orchiectomy | 1 | 1996 | 214 | 0.130 |
Why?
|
| Melanoma | 3 | 2024 | 5317 | 0.130 |
Why?
|
| Nanog Homeobox Protein | 1 | 2015 | 65 | 0.130 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2012 | 1538 | 0.130 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2006 | 1664 | 0.130 |
Why?
|
| Tumor Microenvironment | 4 | 2023 | 2864 | 0.130 |
Why?
|
| Fatigue | 1 | 2021 | 1239 | 0.130 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2015 | 111 | 0.130 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2015 | 107 | 0.130 |
Why?
|
| Acellular Dermis | 1 | 2016 | 103 | 0.130 |
Why?
|
| Gene Amplification | 1 | 2017 | 731 | 0.130 |
Why?
|
| Induction Chemotherapy | 4 | 2022 | 669 | 0.120 |
Why?
|
| Imidazoles | 1 | 2020 | 999 | 0.120 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2015 | 131 | 0.120 |
Why?
|
| Drug Discovery | 1 | 2017 | 324 | 0.120 |
Why?
|
| Lymphopenia | 1 | 2016 | 199 | 0.120 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2015 | 82 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2023 | 639 | 0.120 |
Why?
|
| Spleen | 1 | 2016 | 676 | 0.120 |
Why?
|
| Adolescent | 8 | 2023 | 31252 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 1217 | 0.120 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2005 | 181 | 0.120 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2016 | 287 | 0.120 |
Why?
|
| G1 Phase | 1 | 2015 | 285 | 0.120 |
Why?
|
| Nonsense Mediated mRNA Decay | 1 | 2014 | 38 | 0.120 |
Why?
|
| Gonadal Disorders | 1 | 2013 | 8 | 0.120 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2014 | 103 | 0.120 |
Why?
|
| Thrombocytosis | 1 | 2015 | 121 | 0.120 |
Why?
|
| Transcription Factors | 2 | 2020 | 5270 | 0.120 |
Why?
|
| Radiotherapy | 4 | 2011 | 1824 | 0.120 |
Why?
|
| Organs at Risk | 1 | 2016 | 514 | 0.120 |
Why?
|
| Tissue Fixation | 1 | 2013 | 136 | 0.110 |
Why?
|
| Demography | 1 | 2014 | 435 | 0.110 |
Why?
|
| Formaldehyde | 1 | 2013 | 114 | 0.110 |
Why?
|
| Genes, Neoplasm | 1 | 2014 | 324 | 0.110 |
Why?
|
| Enzyme Activation | 2 | 2007 | 1764 | 0.110 |
Why?
|
| Risk Factors | 10 | 2023 | 17523 | 0.110 |
Why?
|
| Esophagoscopy | 2 | 2006 | 291 | 0.110 |
Why?
|
| Preoperative Period | 3 | 2020 | 344 | 0.110 |
Why?
|
| Paraffin Embedding | 1 | 2013 | 226 | 0.110 |
Why?
|
| Androgen Antagonists | 1 | 1996 | 411 | 0.110 |
Why?
|
| DNA Damage | 1 | 2021 | 1954 | 0.110 |
Why?
|
| Esophageal Diseases | 1 | 1993 | 69 | 0.110 |
Why?
|
| Anilides | 1 | 2015 | 268 | 0.110 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 487 | 0.110 |
Why?
|
| Cell Cycle | 2 | 2015 | 2084 | 0.110 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 1084 | 0.110 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 483 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 907 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 2 | 2005 | 1350 | 0.110 |
Why?
|
| Blotting, Western | 2 | 2016 | 3536 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 607 | 0.110 |
Why?
|
| Prostatic Neoplasms | 3 | 2005 | 5767 | 0.110 |
Why?
|
| Scleroderma, Systemic | 1 | 1993 | 134 | 0.110 |
Why?
|
| Colon | 1 | 2016 | 670 | 0.110 |
Why?
|
| Radiotherapy, Conformal | 3 | 2016 | 902 | 0.100 |
Why?
|
| Diagnosis, Differential | 4 | 2021 | 4744 | 0.100 |
Why?
|
| Piperazines | 1 | 2021 | 2101 | 0.100 |
Why?
|
| Area Under Curve | 5 | 2020 | 700 | 0.100 |
Why?
|
| Endoscopy, Digestive System | 2 | 2010 | 202 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 3639 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2016 | 673 | 0.100 |
Why?
|
| eIF-2 Kinase | 1 | 2012 | 164 | 0.100 |
Why?
|
| Bile | 1 | 2011 | 81 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2014 | 1546 | 0.100 |
Why?
|
| Repressor Proteins | 2 | 2016 | 1664 | 0.100 |
Why?
|
| Hepatectomy | 4 | 2021 | 1011 | 0.100 |
Why?
|
| Adenoma | 1 | 2016 | 716 | 0.100 |
Why?
|
| Alternative Splicing | 1 | 2014 | 584 | 0.100 |
Why?
|
| Disease Management | 1 | 2016 | 1052 | 0.100 |
Why?
|
| Inflammation | 2 | 2022 | 2522 | 0.100 |
Why?
|
| Biomarkers | 3 | 2022 | 5047 | 0.090 |
Why?
|
| RNA, Untranslated | 1 | 2012 | 237 | 0.090 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2016 | 2104 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 669 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 4 | 2017 | 3981 | 0.090 |
Why?
|
| Cell Survival | 2 | 2015 | 3045 | 0.090 |
Why?
|
| Biopsy | 5 | 2018 | 3443 | 0.090 |
Why?
|
| Cancer Vaccines | 1 | 2016 | 697 | 0.090 |
Why?
|
| Somatomedins | 1 | 2010 | 75 | 0.090 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2015 | 986 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2010 | 4549 | 0.090 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2019 | 726 | 0.090 |
Why?
|
| Animals | 7 | 2023 | 59536 | 0.090 |
Why?
|
| Neoplasm Transplantation | 2 | 2018 | 1519 | 0.090 |
Why?
|
| Radiotherapy Dosage | 6 | 2016 | 3842 | 0.090 |
Why?
|
| Endosonography | 1 | 2013 | 536 | 0.090 |
Why?
|
| Isoflavones | 1 | 2010 | 72 | 0.090 |
Why?
|
| Radiography | 3 | 2020 | 1904 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 1143 | 0.090 |
Why?
|
| Pancreas | 1 | 2013 | 718 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 1678 | 0.090 |
Why?
|
| Thymidine Phosphorylase | 1 | 2009 | 23 | 0.090 |
Why?
|
| Carboxylesterase | 1 | 2009 | 33 | 0.090 |
Why?
|
| Cholestasis | 1 | 2011 | 203 | 0.080 |
Why?
|
| Octreotide | 1 | 2009 | 118 | 0.080 |
Why?
|
| Cytidine Deaminase | 1 | 2009 | 83 | 0.080 |
Why?
|
| Laparoscopy | 2 | 2016 | 1225 | 0.080 |
Why?
|
| Taxoids | 2 | 2010 | 967 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2017 | 6150 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 2992 | 0.080 |
Why?
|
| Flow Cytometry | 1 | 2015 | 3033 | 0.080 |
Why?
|
| Doxorubicin | 1 | 2005 | 3005 | 0.080 |
Why?
|
| Neoplasm Grading | 3 | 2018 | 1742 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2021 | 2803 | 0.080 |
Why?
|
| Administration, Intravenous | 2 | 2020 | 249 | 0.080 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2020 | 852 | 0.080 |
Why?
|
| Phenotype | 2 | 2017 | 6295 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 630 | 0.080 |
Why?
|
| Everolimus | 1 | 2010 | 415 | 0.080 |
Why?
|
| Diabetes Complications | 1 | 2010 | 305 | 0.080 |
Why?
|
| Trefoil Factor-3 | 1 | 2007 | 10 | 0.080 |
Why?
|
| Ovarian Neoplasms | 1 | 2024 | 4638 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 5395 | 0.080 |
Why?
|
| Trans-Activators | 1 | 2014 | 1555 | 0.080 |
Why?
|
| Liquid Biopsy | 2 | 2018 | 158 | 0.080 |
Why?
|
| Lymph Node Excision | 4 | 2021 | 1959 | 0.080 |
Why?
|
| Societies, Medical | 2 | 2016 | 1335 | 0.080 |
Why?
|
| Cathartics | 1 | 2007 | 42 | 0.080 |
Why?
|
| Mice | 4 | 2018 | 34495 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2016 | 2022 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 4821 | 0.080 |
Why?
|
| Glucuronates | 1 | 2007 | 11 | 0.080 |
Why?
|
| Tumor Burden | 3 | 2018 | 1987 | 0.080 |
Why?
|
| Patient Selection | 4 | 2021 | 2055 | 0.070 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2005 | 202 | 0.070 |
Why?
|
| CD24 Antigen | 1 | 2007 | 85 | 0.070 |
Why?
|
| Fibronectins | 1 | 2007 | 197 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2011 | 889 | 0.070 |
Why?
|
| Rats, Inbred F344 | 1 | 2007 | 224 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2007 | 125 | 0.070 |
Why?
|
| Neoplastic Stem Cells | 1 | 2015 | 1443 | 0.070 |
Why?
|
| Cohort Studies | 6 | 2020 | 9244 | 0.070 |
Why?
|
| Celecoxib | 1 | 2007 | 200 | 0.070 |
Why?
|
| Vimentin | 1 | 2007 | 253 | 0.070 |
Why?
|
| Genetic Vectors | 1 | 2012 | 1694 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2017 | 4971 | 0.070 |
Why?
|
| Peritoneal Neoplasms | 1 | 2013 | 821 | 0.070 |
Why?
|
| Fatal Outcome | 2 | 2005 | 829 | 0.070 |
Why?
|
| Thiophenes | 1 | 2007 | 148 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2023 | 4849 | 0.070 |
Why?
|
| Salvage Therapy | 3 | 2009 | 2054 | 0.070 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2020 | 565 | 0.070 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2007 | 360 | 0.070 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 2005 | 37 | 0.070 |
Why?
|
| Gated Blood-Pool Imaging | 1 | 2005 | 17 | 0.060 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1998 | 2341 | 0.060 |
Why?
|
| Histamine H1 Antagonists | 1 | 2004 | 25 | 0.060 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2021 | 1064 | 0.060 |
Why?
|
| Esophagogastric Junction | 1 | 2008 | 543 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2004 | 170 | 0.060 |
Why?
|
| Odds Ratio | 3 | 2016 | 2316 | 0.060 |
Why?
|
| Postoperative Period | 2 | 2017 | 665 | 0.060 |
Why?
|
| Postoperative Complications | 2 | 2018 | 5542 | 0.060 |
Why?
|
| S Phase | 1 | 2005 | 281 | 0.060 |
Why?
|
| Administration, Topical | 1 | 2004 | 257 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2009 | 840 | 0.060 |
Why?
|
| Cadherins | 1 | 2007 | 660 | 0.060 |
Why?
|
| Incidental Findings | 2 | 2016 | 272 | 0.060 |
Why?
|
| Ki-67 Antigen | 1 | 2006 | 666 | 0.060 |
Why?
|
| Anticarcinogenic Agents | 1 | 2006 | 362 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 1375 | 0.060 |
Why?
|
| Desensitization, Immunologic | 1 | 2004 | 94 | 0.060 |
Why?
|
| DNA Adducts | 2 | 2014 | 210 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2005 | 447 | 0.060 |
Why?
|
| DNA | 1 | 2012 | 2693 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2022 | 6009 | 0.060 |
Why?
|
| Vomiting | 2 | 2021 | 354 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2017 | 1391 | 0.060 |
Why?
|
| Neuroendocrine Tumors | 1 | 2009 | 634 | 0.060 |
Why?
|
| SEER Program | 1 | 2006 | 1000 | 0.060 |
Why?
|
| Biology | 1 | 2023 | 75 | 0.060 |
Why?
|
| Confidence Intervals | 1 | 2004 | 756 | 0.060 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2024 | 83 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 3869 | 0.060 |
Why?
|
| Cytoplasm | 1 | 2005 | 652 | 0.060 |
Why?
|
| Probability | 1 | 2004 | 866 | 0.050 |
Why?
|
| Steroids | 1 | 2004 | 356 | 0.050 |
Why?
|
| Bilirubin | 1 | 2024 | 221 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2024 | 310 | 0.050 |
Why?
|
| Aspirin | 1 | 2006 | 455 | 0.050 |
Why?
|
| Weight Loss | 1 | 2007 | 627 | 0.050 |
Why?
|
| Age of Onset | 1 | 2004 | 827 | 0.050 |
Why?
|
| Barrett Esophagus | 1 | 2008 | 569 | 0.050 |
Why?
|
| Exanthema | 1 | 2004 | 211 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 980 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2014 | 3552 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 15694 | 0.050 |
Why?
|
| Stroke Volume | 1 | 2005 | 577 | 0.050 |
Why?
|
| V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 1 | 2021 | 29 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2018 | 4654 | 0.050 |
Why?
|
| Hodgkin Disease | 2 | 2005 | 1429 | 0.050 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2021 | 76 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2009 | 1616 | 0.050 |
Why?
|
| Contraindications, Procedure | 1 | 2021 | 8 | 0.050 |
Why?
|
| Fever | 1 | 2004 | 497 | 0.050 |
Why?
|
| Sex Factors | 1 | 2007 | 2139 | 0.050 |
Why?
|
| Liver | 2 | 2021 | 2961 | 0.050 |
Why?
|
| Indoles | 1 | 2007 | 1009 | 0.050 |
Why?
|
| B7 Antigens | 1 | 2021 | 84 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 1054 | 0.050 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 132 | 0.050 |
Why?
|
| Genetic Testing | 2 | 2021 | 1589 | 0.050 |
Why?
|
| HLA-A1 Antigen | 1 | 2020 | 9 | 0.050 |
Why?
|
| Epidemiologic Methods | 1 | 2021 | 254 | 0.050 |
Why?
|
| INDEL Mutation | 1 | 2021 | 112 | 0.050 |
Why?
|
| Quinuclidines | 1 | 2021 | 48 | 0.050 |
Why?
|
| Ecosystem | 1 | 2021 | 111 | 0.050 |
Why?
|
| Isoquinolines | 1 | 2021 | 116 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 1363 | 0.050 |
Why?
|
| Food-Drug Interactions | 1 | 2020 | 22 | 0.050 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2021 | 216 | 0.050 |
Why?
|
| Republic of Korea | 1 | 2020 | 70 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2024 | 842 | 0.050 |
Why?
|
| Kidney | 1 | 2009 | 2146 | 0.050 |
Why?
|
| Electrocardiography | 1 | 2006 | 1145 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2021 | 6869 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 53 | 0.050 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 1 | 2019 | 27 | 0.050 |
Why?
|
| Exercise Therapy | 1 | 2023 | 288 | 0.050 |
Why?
|
| Clonal Evolution | 1 | 2022 | 253 | 0.040 |
Why?
|
| Linear Models | 2 | 2017 | 1085 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2023 | 552 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2005 | 1620 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 2019 | 2483 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2023 | 703 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2023 | 649 | 0.040 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2020 | 100 | 0.040 |
Why?
|
| Research Design | 2 | 2020 | 1544 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2021 | 621 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2012 | 2947 | 0.040 |
Why?
|
| Machine Learning | 1 | 2021 | 319 | 0.040 |
Why?
|
| Nausea | 1 | 2021 | 525 | 0.040 |
Why?
|
| DNA, Neoplasm | 2 | 2014 | 1910 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2020 | 675 | 0.040 |
Why?
|
| Europe | 1 | 2020 | 649 | 0.040 |
Why?
|
| Oncogenes | 1 | 2021 | 673 | 0.040 |
Why?
|
| Heart | 1 | 2005 | 1223 | 0.040 |
Why?
|
| Point Mutation | 1 | 2021 | 769 | 0.040 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2003 | 519 | 0.040 |
Why?
|
| Rats | 1 | 2007 | 6086 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2023 | 2292 | 0.040 |
Why?
|
| Gene Expression | 2 | 2021 | 3570 | 0.040 |
Why?
|
| Radiation Dosage | 2 | 2016 | 1014 | 0.040 |
Why?
|
| Recurrence | 2 | 2018 | 4758 | 0.040 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2019 | 226 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 524 | 0.040 |
Why?
|
| Rectal Neoplasms | 1 | 2005 | 1202 | 0.040 |
Why?
|
| Subcutaneous Fat | 1 | 2018 | 92 | 0.040 |
Why?
|
| Muscles | 1 | 2018 | 416 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2013 | 2307 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2023 | 941 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2018 | 342 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 1033 | 0.040 |
Why?
|
| Organ Size | 1 | 2018 | 690 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 1399 | 0.040 |
Why?
|
| Cholecystitis | 1 | 2016 | 52 | 0.040 |
Why?
|
| Placenta | 1 | 2020 | 516 | 0.040 |
Why?
|
| Logistic Models | 2 | 2016 | 3441 | 0.040 |
Why?
|
| Cattle | 1 | 2018 | 783 | 0.040 |
Why?
|
| CCCTC-Binding Factor | 1 | 2016 | 33 | 0.030 |
Why?
|
| KCNQ1 Potassium Channel | 1 | 2016 | 20 | 0.030 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2016 | 68 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2016 | 64 | 0.030 |
Why?
|
| Injections, Intra-Arterial | 1 | 2005 | 62 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 1146 | 0.030 |
Why?
|
| Breath Holding | 1 | 2015 | 44 | 0.030 |
Why?
|
| Decision Trees | 2 | 2006 | 178 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2016 | 155 | 0.030 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2016 | 107 | 0.030 |
Why?
|
| Liver Failure | 1 | 2016 | 140 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 2594 | 0.030 |
Why?
|
| Texas | 2 | 2020 | 6311 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2018 | 368 | 0.030 |
Why?
|
| Microspheres | 1 | 2005 | 210 | 0.030 |
Why?
|
| Exercise | 1 | 2023 | 1183 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2020 | 1016 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 486 | 0.030 |
Why?
|
| Smad3 Protein | 1 | 2016 | 129 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2021 | 1863 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2005 | 2819 | 0.030 |
Why?
|
| Child | 4 | 2019 | 29154 | 0.030 |
Why?
|
| Gene Components | 1 | 2014 | 16 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2016 | 591 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2014 | 88 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2020 | 1245 | 0.030 |
Why?
|
| Hormones | 1 | 1996 | 266 | 0.030 |
Why?
|
| Margins of Excision | 1 | 2016 | 285 | 0.030 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2014 | 16 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2018 | 1643 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 657 | 0.030 |
Why?
|
| Biological Transport, Active | 1 | 2014 | 131 | 0.030 |
Why?
|
| Family Health | 1 | 2015 | 325 | 0.030 |
Why?
|
| NF-kappa B | 2 | 2012 | 1549 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 1516 | 0.030 |
Why?
|
| Necrosis | 1 | 2005 | 580 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 495 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2016 | 402 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2018 | 785 | 0.030 |
Why?
|
| Internationality | 1 | 2015 | 208 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 521 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2014 | 573 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 7222 | 0.030 |
Why?
|
| Platelet Count | 1 | 2015 | 490 | 0.030 |
Why?
|
| Binding Sites | 1 | 2018 | 2171 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2014 | 448 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2017 | 470 | 0.030 |
Why?
|
| RNA Helicases | 1 | 2014 | 101 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 752 | 0.030 |
Why?
|
| Spasm | 1 | 1993 | 59 | 0.030 |
Why?
|
| Biological Transport | 1 | 2014 | 597 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 1997 | 993 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 875 | 0.030 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2015 | 304 | 0.030 |
Why?
|
| Forecasting | 1 | 1996 | 694 | 0.030 |
Why?
|
| Mutagenesis | 1 | 2014 | 483 | 0.030 |
Why?
|
| Telomerase | 1 | 2016 | 525 | 0.030 |
Why?
|
| ras Proteins | 1 | 2017 | 770 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 402 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2018 | 3203 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2016 | 548 | 0.030 |
Why?
|
| Exons | 1 | 2016 | 1328 | 0.030 |
Why?
|
| Arteriovenous Fistula | 1 | 2013 | 92 | 0.030 |
Why?
|
| Genotype | 2 | 2010 | 4109 | 0.030 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2016 | 591 | 0.030 |
Why?
|
| Injections, Intralesional | 1 | 2012 | 164 | 0.030 |
Why?
|
| Actuarial Analysis | 1 | 2011 | 159 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2017 | 973 | 0.020 |
Why?
|
| Adenoviruses, Human | 1 | 2012 | 181 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2018 | 1648 | 0.020 |
Why?
|
| Eukaryotic Initiation Factor-3 | 1 | 2010 | 15 | 0.020 |
Why?
|
| Tertiary Care Centers | 1 | 2013 | 403 | 0.020 |
Why?
|
| Obesity | 1 | 2023 | 2884 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2016 | 1819 | 0.020 |
Why?
|
| Proteomics | 1 | 2018 | 1380 | 0.020 |
Why?
|
| Sulfonylurea Compounds | 1 | 2010 | 32 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 1656 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2010 | 60 | 0.020 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2011 | 170 | 0.020 |
Why?
|
| Plastics | 1 | 2011 | 93 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2021 | 2967 | 0.020 |
Why?
|
| Metals | 1 | 2011 | 155 | 0.020 |
Why?
|
| Comorbidity | 1 | 2016 | 2352 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2013 | 340 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 2265 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2017 | 1586 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2010 | 132 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2016 | 5687 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 1489 | 0.020 |
Why?
|
| Cetuximab | 1 | 2011 | 472 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 2009 | 95 | 0.020 |
Why?
|
| Pancreatitis | 1 | 2012 | 267 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 3154 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2019 | 2370 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2011 | 749 | 0.020 |
Why?
|
| Cell Movement | 1 | 2016 | 2466 | 0.020 |
Why?
|
| Age Factors | 1 | 2017 | 5377 | 0.020 |
Why?
|
| Infant | 1 | 2023 | 13310 | 0.020 |
Why?
|
| Haplotypes | 1 | 2010 | 856 | 0.020 |
Why?
|
| Base Sequence | 1 | 2014 | 4917 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 7573 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 5637 | 0.020 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2007 | 57 | 0.020 |
Why?
|
| Laryngeal Mucosa | 1 | 2006 | 3 | 0.020 |
Why?
|
| Creatinine | 1 | 2009 | 531 | 0.020 |
Why?
|
| Algorithms | 1 | 2018 | 3890 | 0.020 |
Why?
|
| Capsules | 1 | 2006 | 53 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 7702 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2006 | 191 | 0.020 |
Why?
|
| Outpatients | 1 | 2010 | 462 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2016 | 1330 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2006 | 84 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 6089 | 0.020 |
Why?
|
| Half-Life | 1 | 2006 | 259 | 0.020 |
Why?
|
| New York | 1 | 2006 | 104 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2007 | 256 | 0.020 |
Why?
|
| Bile Ducts | 1 | 2006 | 113 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2006 | 118 | 0.020 |
Why?
|
| Cholelithiasis | 1 | 2006 | 43 | 0.020 |
Why?
|
| Metformin | 1 | 2010 | 378 | 0.020 |
Why?
|
| Life Tables | 1 | 2005 | 120 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2016 | 5710 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 2009 | 629 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 3260 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2005 | 249 | 0.020 |
Why?
|
| Cyclin A | 1 | 2005 | 47 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 2927 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2009 | 1070 | 0.020 |
Why?
|
| Trefoil Factor-2 | 1 | 2005 | 17 | 0.020 |
Why?
|
| Models, Biological | 1 | 2014 | 3254 | 0.020 |
Why?
|
| Remission Induction | 1 | 2011 | 3569 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2005 | 418 | 0.020 |
Why?
|
| Hepatitis B, Chronic | 1 | 2006 | 137 | 0.020 |
Why?
|
| Omentum | 1 | 2004 | 96 | 0.010 |
Why?
|
| Splenic Neoplasms | 1 | 2004 | 119 | 0.010 |
Why?
|
| Gastrectomy | 1 | 2006 | 451 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 521 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 3101 | 0.010 |
Why?
|
| Reoperation | 1 | 2006 | 1382 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2018 | 16273 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 2009 | 1411 | 0.010 |
Why?
|
| Neutropenia | 1 | 2005 | 968 | 0.010 |
Why?
|
| Body Weight | 1 | 2005 | 1293 | 0.010 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2004 | 489 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2013 | 3022 | 0.010 |
Why?
|
| Calcium | 1 | 2005 | 1537 | 0.010 |
Why?
|
| Registries | 1 | 2006 | 2170 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2003 | 1085 | 0.010 |
Why?
|
| Smoking | 1 | 2004 | 2440 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2003 | 4078 | 0.010 |
Why?
|